Clinical Policy: Denosumab (Prolia, Xgeva)
Reference Number: CP.PHAR.58
Effective Date: 03.01.11
Last Review Date: 02.21
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Denosumab (Prolia®, Xgeva®) is a receptor activator of nuclear factor kappa-B ligand inhibitor.

FDA Approved Indication(s)
Prolia is indicated:
- **Postmenopausal osteoporosis (PMO):** For the treatment of postmenopausal women with osteoporosis at high risk for fracture*, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures.
- **Male osteoporosis:** For the treatment to increase bone mass in men with osteoporosis at high risk for fracture*, or patients who have failed or are intolerant to other available osteoporosis therapy.
- **Male osteoporosis - oncology:** For treatment to increase bone mass in men at high risk for fracture* receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures.
- **Female osteoporosis - oncology:** For treatment to increase bone mass in women at high risk for fracture* receiving adjuvant aromatase inhibitor therapy for breast cancer.
- **Glucocorticoid-induced osteoporosis (GIO):** For the treatment of GIO in men and women at high risk of fracture* who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to ≥ 7.5 mg of prednisone and expected to remain on glucocorticoids for ≥ 6 months.

*High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Xgeva is indicated:
- **Multiple myeloma (MM) and solid tumors:** For the prevention of skeletal-related events in patients with MM and in patients with bone metastases from solid tumors.
- **Giant cell tumor of the bone:** For the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
- **Hypercalcemia of malignancy:** For the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Policy/Criteria
*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*
Index
I. Initial Approval Criteria
   A. Osteoporosis (Prolia)
   B. Prostate/Breast Cancer - Fracture Prevention (Prolia)
   C. Multiple Myeloma or Solid Tumor (Xgeva)
   D. Giant Cell Tumor of Bone (Xgeva)
   E. Hypercalcemia of Malignancy (Xgeva)
   F. Systemic Mastocytosis (off-label) (Xgeva)
   G. Other diagnoses/indications
II. Continued Therapy
   A. All Indications in Section I (Prolia and Xgeva)
   B. Other diagnoses/indications
III. Diagnoses/Indications for which coverage is NOT authorized
IV. Appendices/General Information
V. Dosage and Administration
VI. Product Availability
VII. References

It is the policy of health plans affiliated with Centene Corporation® that Prolia and Xgeva are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Osteoporosis (must meet all):
      1. Request is for Prolia;
      2. Diagnosis of PMO, GIO, or male osteoporosis and (a or b):
         a. Member is at very high risk for fracture (i or ii):
            i. BMD T-score at hip or spine ≤ -3.5;
            ii. BMD T-score at hip or spine ≤ -2.5 AND major osteoporotic fracture (i.e., hip, spine, forearm, wrist, humerus);
         b. Member has completed a 3-year trial of bisphosphonate therapy* (alendronate is preferred) at up to maximally indicated doses unless all are contraindicated or clinically significant adverse effects are experienced to both IV and PO formulations (see Appendices B, D);
            *Prior authorization may be required.
      3. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
      4. Prolia is not prescribed concurrently with Xgeva;
      5. Dose does not exceed 60 mg every 6 months.
   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – 6 months or to the member’s renewal date, whichever is longer

   B. Prostate/Breast Cancer - Fracture Prevention (must meet all):
      1. Request is for Prolia;
      2. Diagnosis of one of the following (a or b):
a. Prostate cancer and member is receiving ADT (e.g., leuprolide (Lupron®),
bicalutamide (Casodex®) or Nilandron®));
b. Breast cancer and member is receiving adjuvant endocrine therapy (e.g.,
tamoxifen or aromatase inhibitors such as anastrozole (Arimidex®), exemestane
(Aromasin®) or letrozole (Femara®));
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
5. Member meets one of the following (a or b):
   a. Failure of zoledronic acid* (Zometa® - prostate or breast cancer) or pamidronate*
      (breast cancer) at up to maximally indicated doses unless both are contraindicated
      or clinically significant adverse effects are experienced (Appendices B, D);
      *Prior authorization may be required.
   b. Request is for the treatment associated with Stage IV or metastatic cancer for a
      State with regulations against step therapy in advanced oncology settings (see
      Appendix E);
      Prolia is not prescribed concurrently with Xgeva;
6. Dose does not exceed 60 mg every 6 months.
Approval duration:
Medicaid/HIM – 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

C. Multiple Myeloma or Solid Tumor (must meet all):
1. Request is for Xgeva;
2. Diagnosis of one of the following (a or b):
   a. MM, and member is receiving or initiating therapy (e.g., chemotherapy,
      transplant) for symptomatic disease;
   b. Bone metastasis secondary to solid tumor (e.g., breast, kidney, lung, prostate,
      thyroid);
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
5. For indications other than prostate or breast cancer, member meets one of the
   following (a or b):
   a. Failure of zoledronic acid* (Zometa) or pamidronate* at up to maximally
      indicated doses, unless clinically significant adverse effects are experienced or
      both are contraindicated (Appendices B, D);
      *Prior authorization may be required.
   b. Request is for the treatment associated with Stage IV or metastatic cancer for a
      State with regulations against step therapy in advanced oncology settings (see
      Appendix E);
6. Xgeva is not prescribed concurrently with Prolia;
7. Dose does not exceed 120 mg every 4 weeks.
Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

D. Giant Cell Tumor of Bone (must meet all):
1. Request is for Xgeva;
2. Diagnosis of giant cell tumor of bone (a or b):
   a. Metastatic or unresectable disease;
   b. Localized disease and Xgeva is prescribed as a single agent or in combination
      with interferon alfa or radiation therapy;
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
5. Xgeva is not prescribed concurrently with Prolia;
6. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first
   month of therapy.

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

E. Hypercalcemia of Malignancy (must meet all):
1. Request is for Xgeva;
2. Diagnosis of hypercalcemia of malignancy:
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
5. Albumin-corrected calcium > 12.5 mg/dL despite IV bisphosphonate therapy in the
   last 30 days (Appendix B);
   *Prior authorization may be required.
6. Xgeva is not prescribed concurrently with Prolia;
7. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first
   month of therapy.

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

F. Systemic Mastocytosis (off-label) (must meet all):
1. Request is for Xgeva;
2. Diagnosis of systemic mastocytosis;
3. Member has osteopenia or osteoporosis with bone pain:
4. Prescribed by or in consultation with an oncologist;
5. Age ≥ 18 years or documentation of closed epiphyses on x-ray;
6. Member meets one of the following (a or b):
   a. Failure of zoledronic acid* (Zometa) or pamidronate* at up to maximally
      indicated doses unless clinically significant adverse effects are experienced or
      both are contraindicated (Appendices B, D);
      *Prior authorization may be required.
   b. Request is for the treatment associated with Stage IV or metastatic cancer for a
      State with regulations against step therapy in advanced oncology settings (see
      Appendix E);
7. Xgeva is not prescribed concurrently with Prolia;
8. Dose is within FDA maximum limit for any FDA-approved indication or is supported
   by practice guidelines or peer-reviewed literature for the relevant off-label use
   (prescriber must submit supporting evidence).*
   *Prescribed regimen must be FDA-approved or recommended by NCCN.
Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

G. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
   1. Member meets one of the following (a or b):
      a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
      b. Documentation supports that member is currently receiving Prolia or Xgeva for a covered cancer-related indication and has received this medication for at least 30 days;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed (a or b):
      a. Prolia: 60 mg every 6 months;
      b. Xgeva: 120 mg every 4 weeks or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*
*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration:
Medicaid/HIM – 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IV bisphosphonates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ibandronate (Boniva)</td>
<td>Treatment: PMO Hypercalcemia of malignancy</td>
<td>Varies See prescribing information and compendia for dosing.</td>
</tr>
<tr>
<td>pamidronate</td>
<td>MM Bone metastasis from breast cancer Hypercalcemia of malignancy Systemic mastocytosis (off-label) Fracture prevention – breast/prostate cancer (off-label)</td>
<td></td>
</tr>
<tr>
<td><strong>Oral bisphosphonates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alendronate (Fosamax®)</td>
<td>Treatment/prevention: PMO Treatment: GIO, male osteoporosis Treatment: Paget disease</td>
<td>Varies See prescribing information and compendia for dosing.</td>
</tr>
<tr>
<td>Fosamax® Plus D (alendronate / cholecalciferol)</td>
<td>Treatment: PMO, male osteoporosis</td>
<td></td>
</tr>
<tr>
<td>ibandronate (Boniva®)</td>
<td>Treatment/prevention: PMO</td>
<td></td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.
Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Prolia: hypocalcemia, pregnancy, known hypersensitivity to Prolia
  - Xgeva: hypocalcemia, known clinically significant hypersensitivity to Xgeva
- Boxed warning(s): none reported

Appendix D: IV/PO Bisphosphonates: Examples of Contraindications and Adverse Effects

<table>
<thead>
<tr>
<th>Bisphosphonates</th>
<th>Oral Formulations</th>
<th>IV Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contraindications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Increased risk of aspiration</td>
<td>X</td>
<td>-</td>
</tr>
<tr>
<td>Hypersensitivity to product component</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Inability to stand/sit upright for at least 30 minutes</td>
<td>X</td>
<td>-</td>
</tr>
<tr>
<td>Creatinine clearance &lt; 35 mL/min or evidence of acute renal impairment</td>
<td>-</td>
<td>X</td>
</tr>
<tr>
<td>Esophagus abnormalities which delay emptying such as stricture or achalasia</td>
<td>X</td>
<td>-</td>
</tr>
<tr>
<td><strong>Clinically significant warnings or adverse side effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Eye inflammation</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Osteonecrosis of the jaw</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Atypical femoral shaft fracture</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Drug interactions (product-specific)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Severe or incapacitating musculoskeletal pain</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Appendix E: States with Regulations against Redirections in Stage IV or Metastatic Cancer

<table>
<thead>
<tr>
<th>State</th>
<th>Step Therapy Prohibited?</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FL</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer and associated conditions.</td>
</tr>
<tr>
<td>GA</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.</td>
</tr>
<tr>
<td>IA</td>
<td>Yes</td>
<td>For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.</td>
</tr>
<tr>
<td>LA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer or associated conditions. Exception if “clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.</td>
</tr>
<tr>
<td>OH</td>
<td>Yes</td>
<td><em>Applies to Commercial and HIM requests only</em> For stage 4 metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>PA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer</td>
</tr>
<tr>
<td>TN</td>
<td>Yes</td>
<td>For advanced metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>TX</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer and associated conditions</td>
</tr>
</tbody>
</table>
V. **Dosage and Administration**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denosumab (Prolia)</td>
<td>Treatment: PMO, GIO, male osteoporosis</td>
<td>60 mg SC once every 6 months</td>
<td>60 mg/dose</td>
</tr>
<tr>
<td></td>
<td>Oncology: fracture prevention - Men at high risk for fracture receiving ADT for nonmetastatic prostate cancer - Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denosumab (Xgeva)</td>
<td>MM Solid tumor - bone metastasis</td>
<td>120 mg SC once every 4 weeks</td>
<td>20 mg/dose</td>
</tr>
<tr>
<td></td>
<td>Giant cell tumor of bone Hypercalcemia of malignancy</td>
<td>120 mg SC every 4 weeks plus 120 mg on Days 8 and 15 of first month of therapy</td>
<td>120 mg/dose</td>
</tr>
</tbody>
</table>

VI. **Product Availability**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denosumab (Prolia)</td>
<td>Injection (single-use prefilled syringe): 60 mg/mL</td>
</tr>
<tr>
<td>Denosumab (Xgeva)</td>
<td>Injection (single-use vial): 120 mg/1.7 mL (70 mg/mL)</td>
</tr>
</tbody>
</table>

VII. **References**


**Osteoporosis Diagnosis, Fracture Risk, and Treatment**


Male Osteoporosis

Glucocorticoid-Induced Osteoporosis

Oncology

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPSC Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0897</td>
<td>Injection, denosumab, 1 mg</td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>All indications: Modified age requirement to apply to pediatric members with open epiphyses. Removed requirement for administration of calcium/vitamin D. Removed hypersensitivity contraindication. Split hypocalcemia contraindication into its own criterion and specified time frame for which lab result is acceptable. Osteoporosis: removed criteria related to males with primary osteoporosis or hypogondal osteoporosis, and removed coverage of osteopenic members [T score &lt; -1.0]. Osteoporosis, prostate or breast cancer treatment-induced bone loss: Added “at total hip” to T score; added that osteoporotic fracture should be confirmed by radiographic imaging. Bone metastases, giant cell tumor of bone, hypercalcemia of malignancy: Modified intial/re-auth approval durations from 3/6 months to 6/12 months. Re-auth: Combined Prolia and Xgeva criteria sets; added requirement for documentation of positive response and max dosing; removed reasons to discontinue.</td>
<td>06.17</td>
</tr>
<tr>
<td>2Q2018 annual review: policies combined for commercial and Medicaid lines of business; added HIM line of business to the policy. Commercial: combined CP.CPA.170 (Xgeva) and CP.CPA.202 (Prolia); added age and requirement for no concomitant use of Prolia/Xgeva; modified approval duration from length of benefit to 6 months or to the member’s renewal date, whichever is longer; allowed COC for oncology related indications on re-auth; Osteoporosis: added specialist or failure of an oral bisphosphonate requirement; added trial/failure of zoledronic acid (Reclast); Prostate/Breast Cancer treatment: added requirement related to risk assessment; Hypercalcemia: added lab requirement for albumin-corrected calcium &gt; 12.5 mg/dL. Medicaid: All indications: removed requirements related to pregnancy (for Prolia) and hypocalcemia monitoring; allowed COC for oncology related indications on re-auth; Osteoporosis: Modified diagnosis criterion by removing requirement for evidence of diagnosis; added specialist requirement as an option in lieu of bisphosphonate trial; Criteria added for new FDA indication: multiple myeloma; added Appendix C: Contraindications; references reviewed and updated.</td>
<td>02.20.18</td>
</tr>
<tr>
<td>Criteria added for new FDA indication for Prolia: glucocorticoid-induced osteoporosis; removed requirement for objective diagnosis of high fracture risk osteoporosis in prostate or breast cancer treatment with induced bone loss; references reviewed and updated.</td>
<td>06.26.18</td>
</tr>
<tr>
<td>2Q 2019 annual review: no significant changes; added geriatrician as a prescriber specialist option for osteoporosis; references reviewed and updated.</td>
<td>02.26.19</td>
</tr>
</tbody>
</table>
**Clinical Policy**
Denosumab

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q 2020 annual review: removed HIM disclaimer for HIM NF drugs; Prolia: very high fracture risk or 3-year bisphosphonate trial added with required contraindication to both PO/IV formulations; specialists removed; age 18 or closed epiphyses added per PI; nonmetastatic limitation removed from prostate cancer per NCCN; breast cancer expanded to include men; Xgeva: examples of skeletal related event and solid tumor added; oncologist added; lower age limit and weight restriction removed from giant cell tumor to include NCCN recommended localized disease; NCCN recommended use for systemic mastocytosis added with Zometa trial; hypercalcemia continuation of therapy criteria removed given response fluidity; references reviewed and updated.</td>
<td>11.19.19</td>
<td>02.20</td>
</tr>
<tr>
<td>The MM/solid tumor common criteria line item, at risk for skeletal related event, is removed for solid tumor and for MM is replaced with receiving or initiating therapy for symptomatic disease per pivotal trials/NCCN; IV bisphosphonate trials are added per labels/NCCN to prostate/breast fracture prevention, MM/solid tumor (exception prostate/breast cancer), and systemic mastocytosis.</td>
<td>08.25.20</td>
<td>11.20</td>
</tr>
<tr>
<td>1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.</td>
<td>10.26.20</td>
<td>02.21</td>
</tr>
<tr>
<td>For prostate/breast cancer - fracture prevention, multiple myeloma or solid tumor, and systemic mastocytosis: allowed bypassing of redirection if state regulations do not allow step therapy in Stage IV or metastatic cancer settings.</td>
<td>06.15.21</td>
<td></td>
</tr>
</tbody>
</table>

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and
limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.